desipramine has been researched along with Pain, Chronic in 4 studies
Desipramine: A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.
desipramine : A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This clinical trial evaluated the independent and combined effects of a tricyclic antidepressant (desipramine) and cognitive behavioral therapy (CBT) for chronic back pain relative to an active placebo treatment." | 9.34 | A randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain. ( Atkinson, JH; Capparelli, EV; Chircop-Rollick, T; D'Andrea, J; Funk, SD; Garfin, S; Gould, HM; Patel, SM; Penzien, DB; Rutledge, T; Slater, M; Wallace, M; Weickgenanta, AL, 2020) |
| "This clinical trial evaluated the independent and combined effects of a tricyclic antidepressant (desipramine) and cognitive behavioral therapy (CBT) for chronic back pain relative to an active placebo treatment." | 5.34 | A randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain. ( Atkinson, JH; Capparelli, EV; Chircop-Rollick, T; D'Andrea, J; Funk, SD; Garfin, S; Gould, HM; Patel, SM; Penzien, DB; Rutledge, T; Slater, M; Wallace, M; Weickgenanta, AL, 2020) |
| " 10b was additionally bioavailable following oral dosing and demonstrated efficacy in rat models of acute, inflammatory, and neuropathic pain." | 1.37 | Discovery of novel selective norepinephrine inhibitors: 1-(2-morpholin-2-ylethyl)-3-aryl-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxides (WYE-114152). ( Adedoyin, A; Bray, JA; Deecher, DC; Fensome, A; Goldberg, JA; Harrison, J; Leventhal, L; Mann, C; Mark, L; Nogle, L; O'Neill, DJ; Spangler, TB; Sullivan, NR; Terefenko, EA; Trybulski, EJ; Uveges, AJ; Vu, A; Whiteside, GT; Zhang, P, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| O'Neill, DJ | 1 |
| Adedoyin, A | 1 |
| Bray, JA | 1 |
| Deecher, DC | 1 |
| Fensome, A | 1 |
| Goldberg, JA | 1 |
| Harrison, J | 1 |
| Leventhal, L | 1 |
| Mann, C | 1 |
| Mark, L | 1 |
| Nogle, L | 1 |
| Sullivan, NR | 1 |
| Spangler, TB | 1 |
| Terefenko, EA | 1 |
| Trybulski, EJ | 1 |
| Uveges, AJ | 1 |
| Vu, A | 1 |
| Whiteside, GT | 1 |
| Zhang, P | 1 |
| Gould, HM | 1 |
| Atkinson, JH | 1 |
| Chircop-Rollick, T | 1 |
| D'Andrea, J | 1 |
| Garfin, S | 1 |
| Patel, SM | 1 |
| Funk, SD | 1 |
| Capparelli, EV | 1 |
| Penzien, DB | 1 |
| Wallace, M | 1 |
| Weickgenanta, AL | 1 |
| Slater, M | 1 |
| Rutledge, T | 1 |
| Hearn, L | 1 |
| Moore, RA | 1 |
| Derry, S | 1 |
| Wiffen, PJ | 1 |
| Phillips, T | 1 |
| Rastogi, R | 1 |
| Swarm, RA | 1 |
| Patel, TA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Antidepressants in Chronic Back Pain[NCT00964886] | Phase 2 | 142 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The DDS is self-report measure of current pain intensity of chronic back pain. Participants rate pain on a 20 point scale as being greater or less intense relative to 12 adjectival descriptor words which serve as anchors (eg, greater or less than faint, moderate, strong). Scores range from 0 to 20 with higher scores indicating higher pain intensity. The analysis evaluated the 'as randomized' sample at 12 weeks after baseline or last observation carried forward, after co-varying for baseline (pre-treatment) values." (NCT00964886)
Timeframe: 12 weeks after baseline (or last observation carried forward)
| Intervention | units on a scale (Mean) |
|---|---|
| Arm 1 + Arm 3 | 8.3 |
| Arm 2 + Arm 4 | 8.1 |
| Arm 2 + Arm 3 | 8.0 |
| Arm 1 + Arm 4 | 8.4 |
"This questionnaire measures disability in everyday function due to back pain. It is a 24-item checklist asking patients to endorse whether or not back pain limits activities they normally do (eg, I stay at home most of the time because of my back). Scores range from 0 to 24, with higher scores indicating greater disability in everyday function due to back pain. The analysis evaluated the 'as randomized' sample at 12 weeks after baseline, after co-varying for baseline (pre-treatment) values." (NCT00964886)
Timeframe: 12 weeks after baseline (or last observation carried forward)
| Intervention | Units on a scale. (Mean) |
|---|---|
| Arm 1 + Arm 3 | 8.7 |
| Arm 2 + Arm 4 | 8.9 |
| Arm 2 + Arm 3 | 8.7 |
| Arm 1 + Arm 4 | 8.9 |
2 reviews available for desipramine and Pain, Chronic
| Article | Year |
|---|---|
Desipramine for neuropathic pain in adults.
Topics: Aged; Amitriptyline; Analgesics; Antidepressive Agents, Tricyclic; Chronic Pain; Clomipramine; Desip | 2014 |
Case scenario: opioid association with serotonin syndrome: implications to the practitioners.
Topics: Analgesics, Opioid; Antidepressive Agents, Tricyclic; Celecoxib; Chronic Pain; Cyclooxygenase 2 Inhi | 2011 |
1 trial available for desipramine and Pain, Chronic
| Article | Year |
|---|---|
A randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain.
Topics: Back Pain; Chronic Pain; Cognitive Behavioral Therapy; Desipramine; Humans; Low Back Pain; Treatment | 2020 |
1 other study available for desipramine and Pain, Chronic
| Article | Year |
|---|---|
Discovery of novel selective norepinephrine inhibitors: 1-(2-morpholin-2-ylethyl)-3-aryl-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxides (WYE-114152).
Topics: Acute Pain; Administration, Oral; Analgesics; Animals; Benzothiazoles; Biological Availability; Cell | 2011 |